Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial
2016 ◽
Vol 18
(7)
◽
pp. 711-715
◽
2014 ◽
Vol 28
(3)
◽
pp. 323-327
◽
2017 ◽
Vol 389
(10077)
◽
pp. 1399-1409
◽
Keyword(s):
Keyword(s):
Keyword(s):
2018 ◽
Vol 138
◽
pp. 253-261
◽
Keyword(s):